back
SEDI Insider filing browser
| Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
|---|---|---|---|---|---|---|
| Filed 2023-05-09 19:22 Tx date 2023-05-05 |
$AGN
Algernon Pharmaceuticals Inc. |
Attariwala, Rajpaul
4 - Director of Issuer
Direct Ownership
|
Warrants
57 - Exercise of rights
|
+52,080 vol |
52,080 | |
| Filed 2023-05-09 19:20 Tx date 2023-05-05 |
$AGN
Algernon Pharmaceuticals Inc. |
Attariwala, Rajpaul
4 - Director of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$13,020
+52,080 vol $0.25 each |
114,760 | |
| Filed 2023-05-09 19:20 Tx date 2023-05-05 |
$AGN
Algernon Pharmaceuticals Inc. |
Attariwala, Rajpaul
4 - Director of Issuer
Direct Ownership
|
Rights
58 - Expiration of rights
|
-10,600 vol |
0 | |
| Filed 2023-05-09 19:19 Tx date 2023-05-05 |
$AGN
Algernon Pharmaceuticals Inc. |
Attariwala, Rajpaul
4 - Director of Issuer
Direct Ownership
|
Rights
57 - Exercise of rights
|
-52,080 vol |
10,600 | |
| Filed 2023-05-09 19:17 Tx date 2023-05-05 |
$AGN
Algernon Pharmaceuticals Inc. |
Bloomfield, Harry J.F.
4 - Director of Issuer
Holder: Eldee Foundation (Indirect Ownership)
|
Warrants
57 - Exercise of rights
|
+24,000 vol |
24,000 | |
| Filed 2023-05-09 19:16 Tx date 2021-09-09 |
$AGN
Algernon Pharmaceuticals Inc. |
Bloomfield, Harry J.F.
4 - Director of Issuer
Holder: Eldee Foundation (Indirect Ownership)
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2023-05-09 19:15 Tx date 2023-05-05 |
$AGN
Algernon Pharmaceuticals Inc. |
Bloomfield, Harry J.F.
4 - Director of Issuer
Holder: Eldee Foundation (Indirect Ownership)
|
Common Shares
57 - Exercise of rights
|
$6,000
+24,000 vol $0.25 each |
48,000 | |
| Filed 2023-05-09 19:15 Tx date 2023-05-05 |
$AGN
Algernon Pharmaceuticals Inc. |
Bloomfield, Harry J.F.
4 - Director of Issuer
Holder: Eldee Foundation (Indirect Ownership)
|
Rights
57 - Exercise of rights
|
-24,000 vol |
0 | |
| Filed 2023-05-09 19:13 Tx date 2023-05-05 |
$AGN
Algernon Pharmaceuticals Inc. |
Bloomfield, Harry J.F.
4 - Director of Issuer
Direct Ownership
|
Warrants
57 - Exercise of rights
|
+33,332 vol |
33,332 | |
| Filed 2023-05-09 19:13 Tx date 2021-09-09 |
$AGN
Algernon Pharmaceuticals Inc. |
Bloomfield, Harry J.F.
4 - Director of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2023-05-09 19:12 Tx date 2023-05-05 |
$AGN
Algernon Pharmaceuticals Inc. |
Bloomfield, Harry J.F.
4 - Director of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$8,333
+33,332 vol $0.25 each |
66,664 | |
| Filed 2023-05-09 19:12 Tx date 2023-05-05 |
$AGN
Algernon Pharmaceuticals Inc. |
Bloomfield, Harry J.F.
4 - Director of Issuer
Direct Ownership
|
Rights
57 - Exercise of rights
|
-33,332 vol |
0 | |
| Filed 2023-05-09 19:08 Tx date 2023-05-05 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark
4 - Director of Issuer
Direct Ownership
|
Rights
58 - Expiration of rights
|
-18,132 vol |
0 | |
| Filed 2023-05-09 19:06 Tx date 2023-05-05 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
57 - Exercise of rights
|
+36,034 vol |
36,034 | |
| Filed 2023-05-09 19:06 Tx date 2023-05-05 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$9,008
+36,034 vol $0.25 each |
108,102 | |
| Filed 2023-05-09 19:05 Tx date 2023-05-05 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Rights
58 - Expiration of rights
|
-36,034 vol |
0 | |
| Filed 2023-05-09 19:05 Tx date 2023-05-05 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Rights
57 - Exercise of rights
|
-36,034 vol |
36,034 | |
| Filed 2023-05-09 13:18 Tx date 2023-05-05 |
$AGN
Algernon Pharmaceuticals Inc. |
Kinley, James
5 - Senior Officer of Issuer
Direct Ownership
|
Rights
57 - Exercise of rights
|
$-1,374
-5,496 vol $0.25 each |
0 | |
| Filed 2023-05-09 13:16 Tx date 2023-05-05 |
$AGN
Algernon Pharmaceuticals Inc. |
Kinley, James
5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
57 - Exercise of rights
|
$2,857
+5,496 vol $0.52 each |
5,496 | |
| Filed 2023-05-09 13:15 Tx date 2021-12-01 |
$AGN
Algernon Pharmaceuticals Inc. |
Kinley, James
5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2023-05-09 13:09 Tx date 2023-05-05 |
$AGN
Algernon Pharmaceuticals Inc. |
Kinley, James
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$1,374
+5,496 vol $0.25 each |
10,992 | |
| Filed 2023-04-18 14:19 Tx date 2023-04-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Kinley, James
5 - Senior Officer of Issuer
Direct Ownership
|
Rights
56 - Grant of rights
|
+5,496 vol |
5,496 | |
| Filed 2023-04-18 14:18 Tx date 2021-12-01 |
$AGN
Algernon Pharmaceuticals Inc. |
Kinley, James
5 - Senior Officer of Issuer
Direct Ownership
|
Rights
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2023-04-17 20:09 Tx date 2023-04-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Kinley, James
5 - Senior Officer of Issuer
Direct Ownership
|
Rights RSUs
56 - Grant of rights
|
+5,496 vol |
||
| Filed 2023-04-17 22:03 Tx date 2023-04-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Bloomfield, Harry J.F.
4 - Director of Issuer
Holder: Eldee Foundation (Indirect Ownership)
|
Rights
56 - Grant of rights
|
+24,000 vol |
24,000 | |
| Filed 2023-04-17 22:03 Tx date 2021-09-09 |
$AGN
Algernon Pharmaceuticals Inc. |
Bloomfield, Harry J.F.
4 - Director of Issuer
Holder: Eldee Foundation (Indirect Ownership)
|
Rights
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2023-04-17 22:01 Tx date 2023-04-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Bloomfield, Harry J.F.
4 - Director of Issuer
Direct Ownership
|
Rights
56 - Grant of rights
|
+33,332 vol |
33,332 | |
| Filed 2023-04-17 22:00 Tx date 2021-09-09 |
$AGN
Algernon Pharmaceuticals Inc. |
Bloomfield, Harry J.F.
4 - Director of Issuer
Direct Ownership
|
Rights
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2023-04-17 21:59 Tx date 2023-04-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Attariwala, Rajpaul
4 - Director of Issuer
Direct Ownership
|
Rights
56 - Grant of rights
|
+62,680 vol |
62,680 | |
| Filed 2023-04-17 21:59 Tx date 2015-10-26 |
$AGN
Algernon Pharmaceuticals Inc. |
Attariwala, Rajpaul
4 - Director of Issuer
Direct Ownership
|
Rights
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2023-04-17 21:58 Tx date 2023-04-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark
4 - Director of Issuer
Direct Ownership
|
Rights
56 - Grant of rights
|
+18,132 vol |
18,132 | |
| Filed 2023-04-17 21:57 Tx date 2021-09-16 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark
4 - Director of Issuer
Direct Ownership
|
Rights
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2023-04-17 21:56 Tx date 2023-04-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Rights
56 - Grant of rights
|
+72,068 vol |
72,068 | |
| Filed 2023-04-17 21:55 Tx date 2018-03-01 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Rights
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2023-04-17 20:09 Tx date 2023-04-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Kinley, James
5 - Senior Officer of Issuer
Direct Ownership
|
Rights RSUs
56 - Grant of rights
|
+5,496 vol |
125,496 | |
| Filed 2023-03-19 20:32 Tx date 2023-03-14 |
$AGN
Algernon Pharmaceuticals Inc. |
Gutman, Howard
4 - Director of Issuer
Direct Ownership
|
Rights RSUs
57 - Exercise of rights
|
-13,332 vol |
26,668 | |
| Filed 2023-03-19 20:31 Tx date 2023-03-14 |
$AGN
Algernon Pharmaceuticals Inc. |
Gutman, Howard
4 - Director of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
+13,332 vol |
21,512 | |
| Filed 2023-03-14 13:35 Tx date 2023-03-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Bloomfield, Harry J.F.
4 - Director of Issuer
Direct Ownership
|
Rights RSUs
37 - Stock split or consolidation
|
+50,001 vol |
66,668 | |
| Filed 2023-03-14 13:34 Tx date 2023-03-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Bloomfield, Harry J.F.
4 - Director of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
+45,000 vol |
100,000 | |
| Filed 2023-03-14 13:33 Tx date 2023-03-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Bloomfield, Harry J.F.
4 - Director of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
+30,000 vol |
55,000 | |
| Filed 2023-03-14 13:32 Tx date 2023-03-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Bloomfield, Harry J.F.
4 - Director of Issuer
Holder: Eldee Foundation (Indirect Ownership)
|
Common Shares
37 - Stock split or consolidation
|
+18,000 vol |
24,000 | |
| Filed 2023-03-14 13:31 Tx date 2023-03-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Bloomfield, Harry J.F.
4 - Director of Issuer
Direct Ownership
|
Common Shares
37 - Stock split or consolidation
|
+24,999 vol |
33,332 | |
| Filed 2023-03-14 13:29 Tx date 2023-03-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Attariwala, Rajpaul
4 - Director of Issuer
Direct Ownership
|
Rights RSUs
37 - Stock split or consolidation
|
+20,001 vol |
26,668 | |
| Filed 2023-03-14 13:28 Tx date 2023-03-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Attariwala, Rajpaul
4 - Director of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
+15,000 vol |
62,000 | |
| Filed 2023-03-14 13:27 Tx date 2023-03-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Attariwala, Rajpaul
4 - Director of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
+19,500 vol |
47,000 | |
| Filed 2023-03-14 13:26 Tx date 2023-03-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Attariwala, Rajpaul
4 - Director of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
+6,000 vol |
27,500 | |
| Filed 2023-03-14 13:25 Tx date 2023-03-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Attariwala, Rajpaul
4 - Director of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
+6,000 vol |
21,500 | |
| Filed 2023-03-14 13:24 Tx date 2023-03-01 |
$AGN
Algernon Pharmaceuticals Inc. |
Attariwala, Rajpaul
4 - Director of Issuer
Direct Ownership
|
Options
55 - Expiration of warrants
|
-500 vol |
15,500 | |
| Filed 2023-03-14 13:24 Tx date 2022-05-18 |
$AGN
Algernon Pharmaceuticals Inc. |
Attariwala, Rajpaul
4 - Director of Issuer
Direct Ownership
|
Options
55 - Expiration of warrants
|
-500 vol |
11,000 | |
| Filed 2023-03-14 13:23 Tx date 2023-03-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Attariwala, Rajpaul
4 - Director of Issuer
Direct Ownership
|
Common Shares
37 - Stock split or consolidation
|
+47,010 vol |
62,680 | |
| Filed 2023-03-14 13:20 Tx date 2023-03-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark
4 - Director of Issuer
Direct Ownership
|
Rights RSUs
37 - Stock split or consolidation
|
+20,001 vol |
26,668 | |
| Filed 2023-03-14 13:19 Tx date 2023-03-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark
4 - Director of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
+15,000 vol |
46,000 | |
| Filed 2023-03-14 13:19 Tx date 2023-03-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark
4 - Director of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
+19,500 vol |
31,000 | |
| Filed 2023-03-14 13:18 Tx date 2023-03-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark
4 - Director of Issuer
Direct Ownership
|
Common Shares
37 - Stock split or consolidation
|
+13,599 vol |
18,132 | |
| Filed 2023-03-14 13:14 Tx date 2023-03-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
+60,000 vol |
278,000 | |
| Filed 2023-03-14 13:13 Tx date 2023-03-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
+96,000 vol |
218,000 | |
| Filed 2023-03-14 13:12 Tx date 2023-03-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
+37,500 vol |
122,000 | |
| Filed 2023-03-14 13:11 Tx date 2023-03-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
+15,000 vol |
84,500 | |
| Filed 2023-03-14 13:09 Tx date 2023-03-01 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
55 - Expiration of warrants
|
-2,500 vol |
69,500 | |
| Filed 2023-03-14 13:08 Tx date 2023-03-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Rights RSUs
37 - Stock split or consolidation
|
+180,000 vol |
240,000 | |
| Filed 2023-03-14 13:03 Tx date 2023-03-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
37 - Stock split or consolidation
|
+54,051 vol |
72,068 | |
| Filed 2023-03-14 13:01 Tx date 2023-03-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Gutman, Howard
4 - Director of Issuer
Direct Ownership
|
Rights RSUs
37 - Stock split or consolidation
|
+30,000 vol |
40,000 | |
| Filed 2023-03-14 13:00 Tx date 2023-03-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Gutman, Howard
4 - Director of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
+30,000 vol |
40,000 | |
| Filed 2023-03-14 12:58 Tx date 2023-03-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Gutman, Howard
4 - Director of Issuer
Direct Ownership
|
Common Shares
37 - Stock split or consolidation
|
+6,135 vol |
8,180 | |
| Filed 2023-03-14 12:56 Tx date 2023-03-13 |
$AGN
Algernon Pharmaceuticals Inc. |
BRYAN, CHRISTOPHER
5 - Senior Officer of Issuer
Direct Ownership
|
Rights RSUs
37 - Stock split or consolidation
|
+90,000 vol |
120,000 | |
| Filed 2023-03-14 12:55 Tx date 2023-03-13 |
$AGN
Algernon Pharmaceuticals Inc. |
BRYAN, CHRISTOPHER
5 - Senior Officer of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
+30,000 vol |
104,000 | |
| Filed 2023-03-14 12:53 Tx date 2023-03-13 |
$AGN
Algernon Pharmaceuticals Inc. |
BRYAN, CHRISTOPHER
5 - Senior Officer of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
+40,500 vol |
74,000 | |
| Filed 2023-03-14 12:52 Tx date 2023-03-13 |
$AGN
Algernon Pharmaceuticals Inc. |
BRYAN, CHRISTOPHER
5 - Senior Officer of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
+7,500 vol |
33,500 | |
| Filed 2023-03-13 15:27 Tx date 2023-03-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Kinley, James
5 - Senior Officer of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
$41,512
+40,500 vol $1.02 each |
94,000 | |
| Filed 2023-03-13 15:26 Tx date 2023-03-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Kinley, James
5 - Senior Officer of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
$40,425
+30,000 vol $1.35 each |
53,500 | |
| Filed 2023-03-13 15:24 Tx date 2023-03-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Kinley, James
5 - Senior Officer of Issuer
Direct Ownership
|
Rights RSUs
37 - Stock split or consolidation
|
+90,000 vol |
120,000 | |
| Filed 2023-03-13 15:22 Tx date 2023-03-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Kinley, James
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
37 - Stock split or consolidation
|
+4,122 vol |
5,496 | |
| Filed 2023-01-16 17:06 Tx date 2023-01-16 |
$AGN
Algernon Pharmaceuticals Inc. |
Bloomfield, Harry J.F.
4 - Director of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
+8,333 vol |
8,333 | |
| Filed 2023-01-16 17:06 Tx date 2021-09-09 |
$AGN
Algernon Pharmaceuticals Inc. |
Bloomfield, Harry J.F.
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2023-01-16 17:06 Tx date 2023-01-16 |
$AGN
Algernon Pharmaceuticals Inc. |
Bloomfield, Harry J.F.
4 - Director of Issuer
Direct Ownership
|
Rights RSUs
57 - Exercise of rights
|
-8,333 vol |
16,667 | |
| Filed 2023-01-16 17:04 Tx date 2023-01-16 |
$AGN
Algernon Pharmaceuticals Inc. |
Attariwala, Rajpaul
4 - Director of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
+3,333 vol |
15,670 | |
| Filed 2023-01-16 17:03 Tx date 2023-01-16 |
$AGN
Algernon Pharmaceuticals Inc. |
Attariwala, Rajpaul
4 - Director of Issuer
Direct Ownership
|
Rights RSUs
57 - Exercise of rights
|
-3,333 vol |
6,667 | |
| Filed 2023-01-16 17:02 Tx date 2023-01-16 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark
4 - Director of Issuer
Direct Ownership
|
Common Shares
51 - Exercise of options
|
+3,333 vol |
4,533 | |
| Filed 2023-01-16 17:01 Tx date 2023-01-16 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark
4 - Director of Issuer
Direct Ownership
|
Rights RSUs
57 - Exercise of rights
|
-3,333 vol |
6,667 | |
| Filed 2022-09-05 19:11 Tx date 2022-08-31 |
$AGN
Algernon Pharmaceuticals Inc. |
Bloomfield, Harry J.F.
4 - Director of Issuer
Direct Ownership
|
Rights RSUs
56 - Grant of rights
|
+25,000 vol |
25,000 | |
| Filed 2022-09-05 19:11 Tx date 2021-09-09 |
$AGN
Algernon Pharmaceuticals Inc. |
Bloomfield, Harry J.F.
4 - Director of Issuer
Direct Ownership
|
Rights RSUs
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2022-09-05 19:11 Tx date 2022-08-31 |
$AGN
Algernon Pharmaceuticals Inc. |
Bloomfield, Harry J.F.
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+15,000 vol |
25,000 | |
| Filed 2022-09-05 19:08 Tx date 2022-08-31 |
$AGN
Algernon Pharmaceuticals Inc. |
Attariwala, Rajpaul
4 - Director of Issuer
Direct Ownership
|
Rights RSUs
56 - Grant of rights
|
+10,000 vol |
10,000 | |
| Filed 2022-09-05 19:07 Tx date 2022-08-31 |
$AGN
Algernon Pharmaceuticals Inc. |
Attariwala, Rajpaul
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+5,000 vol |
16,500 | |
| Filed 2022-09-05 19:04 Tx date 2022-08-31 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark
4 - Director of Issuer
Direct Ownership
|
Rights RSUs
56 - Grant of rights
|
+10,000 vol |
10,000 | |
| Filed 2022-09-05 19:04 Tx date 2022-08-31 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+5,000 vol |
11,500 | |
| Filed 2022-09-05 19:02 Tx date 2022-08-31 |
$AGN
Algernon Pharmaceuticals Inc. |
Gutman, Howard
4 - Director of Issuer
Direct Ownership
|
Rights RSUs
56 - Grant of rights
|
+10,000 vol |
10,000 | |
| Filed 2022-09-05 19:01 Tx date 2022-08-31 |
$AGN
Algernon Pharmaceuticals Inc. |
Gutman, Howard
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+10,000 vol |
10,000 | |
| Filed 2022-09-05 18:59 Tx date 2022-08-31 |
$AGN
Algernon Pharmaceuticals Inc. |
BRYAN, CHRISTOPHER
5 - Senior Officer of Issuer
Direct Ownership
|
Rights RSUs
56 - Grant of rights
|
+30,000 vol |
30,000 | |
| Filed 2022-09-05 18:58 Tx date 2022-08-31 |
$AGN
Algernon Pharmaceuticals Inc. |
BRYAN, CHRISTOPHER
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+10,000 vol |
26,000 | |
| Filed 2022-09-05 18:56 Tx date 2022-08-31 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Rights RSUs
56 - Grant of rights
|
+60,000 vol |
60,000 | |
| Filed 2022-09-05 18:55 Tx date 2022-08-31 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+20,000 vol |
72,000 | |
| Filed 2022-09-05 18:03 Tx date 2022-08-31 |
$AGN
Algernon Pharmaceuticals Inc. |
Kinley, James
5 - Senior Officer of Issuer
Direct Ownership
|
Rights RSUs
56 - Grant of rights
|
+30,000 vol |
30,000 | |
| Filed 2022-09-05 18:02 Tx date 2021-12-01 |
$AGN
Algernon Pharmaceuticals Inc. |
Kinley, James
5 - Senior Officer of Issuer
Direct Ownership
|
Rights RSUs
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2022-09-05 18:01 Tx date 2022-08-31 |
$AGN
Algernon Pharmaceuticals Inc. |
Kinley, James
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$53,900
+10,000 vol $5.39 each |
23,500 | |
| Filed 2022-04-18 13:32 Tx date 2022-04-12 |
$AGN
Algernon Pharmaceuticals Inc. |
Bloomfield, Harry J.F.
4 - Director of Issuer
Holder: Eldee Foundation (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$3,630
+600 vol $6.05 each |
6,000 | |
| Filed 2022-04-17 17:26 Tx date 2022-04-12 |
$AGN
Algernon Pharmaceuticals Inc. |
Bloomfield, Harry J.F.
4 - Director of Issuer
Holder: Eldee Foundation (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$363,000
+600 vol $605.00 each |
||
| Filed 2022-04-17 17:26 Tx date 2022-04-12 |
$AGN
Algernon Pharmaceuticals Inc. |
Bloomfield, Harry J.F.
4 - Director of Issuer
Holder: Eldee Foundation (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$363,000
+600 vol $605.00 each |
6,000 | |
| Filed 2022-04-17 17:25 Tx date 2022-04-11 |
$AGN
Algernon Pharmaceuticals Inc. |
Bloomfield, Harry J.F.
4 - Director of Issuer
Holder: Eldee Foundation (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$2,420
+400 vol $6.05 each |
5,400 | |
| Filed 2022-04-14 12:41 Tx date 2022-04-12 |
$AGN
Algernon Pharmaceuticals Inc. |
Attariwala, Rajpaul
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$5,607
+900 vol $6.23 each |
12,337 | |
| Filed 2022-04-14 12:38 Tx date 2022-04-11 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$1,220
+200 vol $6.10 each |
1,200 | |
| Filed 2022-04-08 19:06 Tx date 2022-04-08 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$3,075
+500 vol $6.15 each |
1,000 | |
| Filed 2022-04-08 19:06 Tx date 2022-04-07 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$3,100
+500 vol $6.20 each |
500 | |
| Filed 2022-04-08 16:10 Tx date 2022-02-28 |
$AGN
Algernon Pharmaceuticals Inc. |
Gutman, Howard
4 - Director of Issuer
Direct Ownership
|
Rights RSUs
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2022-04-08 16:09 Tx date 2022-02-28 |
$AGN
Algernon Pharmaceuticals Inc. |
Gutman, Howard
4 - Director of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2022-04-08 16:09 Tx date 2022-02-28 |
$AGN
Algernon Pharmaceuticals Inc. |
Gutman, Howard
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2022-04-08 16:09 Tx date 2022-04-06 |
$AGN
Algernon Pharmaceuticals Inc. |
Gutman, Howard
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$12,822
+2,045 vol $6.27 each |
2,045 | |
| Filed 2022-04-08 16:08 Tx date 2022-02-28 |
$AGN
Algernon Pharmaceuticals Inc. |
Gutman, Howard
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2022-04-05 18:44 Tx date 2022-04-05 |
$AGN
Algernon Pharmaceuticals Inc. |
Kinley, James
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$1,525
+250 vol $6.10 each |
1,374 | |
| Filed 2022-04-05 18:43 Tx date 2022-04-05 |
$AGN
Algernon Pharmaceuticals Inc. |
Kinley, James
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$3,100
+500 vol $6.20 each |
1,124 | |
| Filed 2022-04-05 18:43 Tx date 2022-04-04 |
$AGN
Algernon Pharmaceuticals Inc. |
Kinley, James
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$599.00
+100 vol $5.99 each |
624 | |
| Filed 2022-04-05 18:42 Tx date 2022-04-04 |
$AGN
Algernon Pharmaceuticals Inc. |
Kinley, James
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$3,000
+500 vol $6.00 each |
524 | |
| Filed 2022-03-28 18:51 Tx date 2022-03-28 |
$AGN
Algernon Pharmaceuticals Inc. |
Bloomfield, Harry J.F.
4 - Director of Issuer
Holder: Eldee Foundation (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$5,641
+1,000 vol $5.64 each |
5,000 | |
| Filed 2022-03-28 18:50 Tx date 2022-03-25 |
$AGN
Algernon Pharmaceuticals Inc. |
Bloomfield, Harry J.F.
4 - Director of Issuer
Holder: Eldee Foundation (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$10,594
+2,000 vol $5.30 each |
4,000 | |
| Filed 2022-01-24 13:23 Tx date 2021-03-01 |
$AGN
Algernon Pharmaceuticals Inc. |
BRYAN, CHRISTOPHER
5 - Senior Officer of Issuer
Direct Ownership
|
Rights RSUs
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2022-01-24 13:23 Tx date 2021-03-01 |
$AGN
Algernon Pharmaceuticals Inc. |
BRYAN, CHRISTOPHER
5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2022-01-24 13:22 Tx date 2022-01-01 |
$AGN
Algernon Pharmaceuticals Inc. |
BRYAN, CHRISTOPHER
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+13,500 vol |
16,000 | |
| Filed 2022-01-24 13:21 Tx date 2021-11-23 |
$AGN
Algernon Pharmaceuticals Inc. |
BRYAN, CHRISTOPHER
5 - Senior Officer of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
-247,500 vol |
2,500 | |
| Filed 2022-01-24 13:21 Tx date 2021-03-01 |
$AGN
Algernon Pharmaceuticals Inc. |
BRYAN, CHRISTOPHER
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
250,000 | ||
| Filed 2022-01-24 13:20 Tx date 2021-03-01 |
$AGN
Algernon Pharmaceuticals Inc. |
BRYAN, CHRISTOPHER
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2022-01-24 11:15 Tx date 2021-08-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Levine, David
4 - Director of Issuer
Direct Ownership
|
Rights RSUs
57 - Exercise of rights
|
-85,000 vol |
0 | |
| Filed 2022-01-21 19:58 Tx date 2021-08-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Attariwala, Rajpaul
4 - Director of Issuer
Direct Ownership
|
Rights RSUs
57 - Exercise of rights
|
-85,000 vol |
0 | |
| Filed 2022-01-21 19:57 Tx date 2022-01-01 |
$AGN
Algernon Pharmaceuticals Inc. |
Attariwala, Rajpaul
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+6,500 vol |
11,500 | |
| Filed 2022-01-21 19:56 Tx date 2021-11-23 |
$AGN
Algernon Pharmaceuticals Inc. |
Attariwala, Rajpaul
4 - Director of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
-495,000 vol |
5,000 | |
| Filed 2022-01-21 19:54 Tx date 2021-11-23 |
$AGN
Algernon Pharmaceuticals Inc. |
Attariwala, Rajpaul
4 - Director of Issuer
Direct Ownership
|
Common Shares
37 - Stock split or consolidation
|
-1,132,285 vol |
11,437 | |
| Filed 2022-01-21 19:49 Tx date 2022-01-01 |
$AGN
Algernon Pharmaceuticals Inc. |
Bloomfield, Harry J.F.
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+10,000 vol |
10,000 | |
| Filed 2022-01-21 19:46 Tx date 2021-09-09 |
$AGN
Algernon Pharmaceuticals Inc. |
Bloomfield, Harry J.F.
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2022-01-21 19:38 Tx date 2022-01-01 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+6,500 vol |
6,500 | |
| Filed 2022-01-21 19:37 Tx date 2021-09-16 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark
4 - Director of Issuer
Direct Ownership
|
Rights RSUs
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2022-01-21 19:37 Tx date 2021-09-16 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark
4 - Director of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2022-01-21 19:37 Tx date 2021-09-16 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2022-01-21 19:37 Tx date 2021-09-16 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2022-01-21 19:31 Tx date 2021-08-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Rights RSUs
57 - Exercise of rights
|
-425,000 vol |
0 | |
| Filed 2022-01-21 19:09 Tx date 2022-01-01 |
$AGN
Algernon Pharmaceuticals Inc. |
Levine, David
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+6,500 vol |
11,500 | |
| Filed 2022-01-21 19:08 Tx date 2021-11-23 |
$AGN
Algernon Pharmaceuticals Inc. |
Levine, David
4 - Director of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
-495,000 vol |
5,000 | |
| Filed 2022-01-21 19:07 Tx date 2021-11-23 |
$AGN
Algernon Pharmaceuticals Inc. |
Levine, David
4 - Director of Issuer
Direct Ownership
|
Common Shares
37 - Stock split or consolidation
|
-142,285 vol |
1,437 | |
| Filed 2022-01-20 13:10 Tx date 2022-01-01 |
$AGN
Algernon Pharmaceuticals Inc. |
Kinley, James
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$55,349
+13,500 vol $4.10 each |
13,500 | |
| Filed 2022-01-20 13:08 Tx date 2021-12-01 |
$AGN
Algernon Pharmaceuticals Inc. |
Kinley, James
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2022-01-17 12:41 Tx date 2022-01-01 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+32,000 vol |
52,000 | |
| Filed 2022-01-17 12:39 Tx date 2022-01-12 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$3,769
+640 vol $5.89 each |
18,017 | |
| Filed 2022-01-17 12:37 Tx date 2021-11-24 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$4,000
+800 vol $5.00 each |
15,327 | |
| Filed 2021-11-30 22:14 Tx date 2021-11-24 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$24,000
+4,800 vol $5.00 each |
||
| Filed 2022-01-07 14:47 Tx date 2022-01-07 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$500.00
+100 vol $5.00 each |
21,377 | |
| Filed 2022-01-07 14:47 Tx date 2022-01-06 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$107.75
+25 vol $4.31 each |
21,277 | |
| Filed 2022-01-07 14:46 Tx date 2022-01-06 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$990.00
+225 vol $4.40 each |
21,252 | |
| Filed 2021-12-31 13:11 Tx date 2021-12-31 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$2,170
+500 vol $4.34 each |
21,027 | |
| Filed 2021-12-30 18:07 Tx date 2021-12-01 |
$AGN
Algernon Pharmaceuticals Inc. |
Kinley, James
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
24 | ||
| Filed 2021-12-30 16:06 Tx date 2021-11-30 |
$AGN
Algernon Pharmaceuticals Inc. |
Bloomfield, Harry J.F.
4 - Director of Issuer
Holder: Eldee Foundation (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$7,000
+1,400 vol $5.00 each |
2,000 | |
| Filed 2021-12-30 16:05 Tx date 2021-11-24 |
$AGN
Algernon Pharmaceuticals Inc. |
Bloomfield, Harry J.F.
4 - Director of Issuer
Holder: Eldee Foundation (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$3,000
+600 vol $5.00 each |
600 | |
| Filed 2021-12-30 16:04 Tx date 2021-09-09 |
$AGN
Algernon Pharmaceuticals Inc. |
Bloomfield, Harry J.F.
4 - Director of Issuer
Holder: Eldee Foundation (Indirect Ownership)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2021-12-16 14:42 Tx date 2021-12-16 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$2,000
+400 vol $5.00 each |
20,527 | |
| Filed 2021-12-16 10:39 Tx date 2021-12-15 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$1,040
+200 vol $5.20 each |
20,127 | |
| Filed 2021-12-16 10:39 Tx date 2021-12-15 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$1,100
+200 vol $5.50 each |
19,927 | |
| Filed 2021-12-16 10:38 Tx date 2021-12-15 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$1,142
+200 vol $5.71 each |
19,727 | |
| Filed 2021-11-30 22:15 Tx date 2021-11-24 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
-1,980,000 vol |
20,000 | |
| Filed 2021-11-30 22:14 Tx date 2021-11-29 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$1,098
+200 vol $5.49 each |
19,527 | |
| Filed 2021-11-30 22:14 Tx date 2021-11-24 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$24,000
+4,800 vol $5.00 each |
19,327 | |
| Filed 2021-11-30 22:13 Tx date 2021-11-24 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
37 - Stock split or consolidation
|
-1,438,250 vol |
14,527 | |
| Filed 2021-11-21 14:26 Tx date 2021-11-19 |
$AGN
Algernon Pharmaceuticals Inc. |
Sadhra, Michael
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-15,840
-288,000 vol $0.055 each |
57,000 | |
| Filed 2021-11-21 14:26 Tx date 2021-11-17 |
$AGN
Algernon Pharmaceuticals Inc. |
Sadhra, Michael
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-210.00
-3,000 vol $0.07 each |
345,000 | |
| Filed 2021-11-05 16:52 Tx date 2021-11-01 |
$AGN
Algernon Pharmaceuticals Inc. |
Sadhra, Michael
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,040
-13,000 vol $0.08 each |
348,000 | |
| Filed 2021-10-22 16:24 Tx date 2021-10-21 |
$AGN
Algernon Pharmaceuticals Inc. |
Sadhra, Michael
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-3,200
-40,000 vol $0.08 each |
416,000 | |
| Filed 2021-10-16 13:21 Tx date 2021-10-12 |
$AGN
Algernon Pharmaceuticals Inc. |
Sadhra, Michael
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-340.00
-4,000 vol $0.085 each |
456,000 | |
| Filed 2021-10-08 16:36 Tx date 2021-10-07 |
$AGN
Algernon Pharmaceuticals Inc. |
Sadhra, Michael
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-3,286.695
-38,667 vol $0.085 each |
460,000 | |
| Filed 2021-10-08 16:36 Tx date 2021-10-04 |
$AGN
Algernon Pharmaceuticals Inc. |
Sadhra, Michael
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-3,150
-35,000 vol $0.09 each |
498,667 | |
| Filed 2021-10-07 16:15 Tx date 2021-10-01 |
$AGN
Algernon Pharmaceuticals Inc. |
Sadhra, Michael
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-2,250
-25,000 vol $0.09 each |
533,667 | |
| Filed 2021-10-07 16:15 Tx date 2021-09-28 |
$AGN
Algernon Pharmaceuticals Inc. |
Sadhra, Michael
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-475.00
-5,000 vol $0.095 each |
558,667 | |
| Filed 2021-10-07 16:14 Tx date 2021-09-24 |
$AGN
Algernon Pharmaceuticals Inc. |
Sadhra, Michael
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-4,085
-43,000 vol $0.095 each |
563,667 | |
| Filed 2021-08-10 23:05 Tx date 2021-02-01 |
$AGN
Algernon Pharmaceuticals Inc. |
Levine, David
4 - Director of Issuer
Direct Ownership
|
Options
52 - Expiration of options
|
-200,000 vol |
500,000 | |
| Filed 2021-08-10 23:03 Tx date 2021-02-01 |
$AGN
Algernon Pharmaceuticals Inc. |
Sadhra, Michael
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
52 - Expiration of options
|
-200,000 vol |
2,200,000 | |
| Filed 2021-02-19 14:23 Tx date 2018-10-17 |
$AGN
Algernon Pharmaceuticals Inc. |
Attariwala, Rajpaul
4 - Director of Issuer
Direct Ownership
|
Common Shares
37 - Stock split or consolidation
|
-1,000,000 vol |
1,000,000 | |
| Filed 2021-02-19 14:22 Tx date 2021-01-21 |
$AGN
Algernon Pharmaceuticals Inc. |
Attariwala, Rajpaul
4 - Director of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
+73,118 vol |
1,143,722 | |
| Filed 2021-02-19 14:22 Tx date 2020-09-29 |
$AGN
Algernon Pharmaceuticals Inc. |
Attariwala, Rajpaul
4 - Director of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
+70,604 vol |
1,070,604 | |
| Filed 2021-02-19 14:21 Tx date 2021-01-21 |
$AGN
Algernon Pharmaceuticals Inc. |
Attariwala, Rajpaul
4 - Director of Issuer
Direct Ownership
|
Rights RSUs
57 - Exercise of rights
|
-82,500 vol |
85,000 | |
| Filed 2021-02-19 14:20 Tx date 2020-09-29 |
$AGN
Algernon Pharmaceuticals Inc. |
Attariwala, Rajpaul
4 - Director of Issuer
Direct Ownership
|
Rights RSUs
57 - Exercise of rights
|
-82,500 vol |
167,500 | |
| Filed 2021-02-19 14:17 Tx date 2020-07-23 |
$AGN
Algernon Pharmaceuticals Inc. |
Attariwala, Rajpaul
4 - Director of Issuer
Direct Ownership
|
Rights RSUs
56 - Grant of rights
|
+250,000 vol |
250,000 | |
| Filed 2021-02-19 14:17 Tx date 2015-10-26 |
$AGN
Algernon Pharmaceuticals Inc. |
Attariwala, Rajpaul
4 - Director of Issuer
Direct Ownership
|
Rights RSUs
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2021-02-19 14:15 Tx date 2020-10-26 |
$AGN
Algernon Pharmaceuticals Inc. |
Attariwala, Rajpaul
4 - Director of Issuer
Direct Ownership
|
Warrants
55 - Expiration of warrants
|
-1,000,000 vol |
0 | |
| Filed 2021-02-19 14:13 Tx date 2020-04-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Attariwala, Rajpaul
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+200,000 vol |
750,000 | |
| Filed 2021-02-19 14:11 Tx date 2018-10-17 |
$AGN
Algernon Pharmaceuticals Inc. |
Attariwala, Rajpaul
4 - Director of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
-50,000 vol |
350,000 | |
| Filed 2021-02-19 14:10 Tx date 2018-10-17 |
$AGN
Algernon Pharmaceuticals Inc. |
Attariwala, Rajpaul
4 - Director of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
-50,000 vol |
400,000 | |
| Filed 2021-02-19 14:08 Tx date 2021-02-01 |
$AGN
Algernon Pharmaceuticals Inc. |
Attariwala, Rajpaul
4 - Director of Issuer
Direct Ownership
|
Options
52 - Expiration of options
|
-250,000 vol |
500,000 | |
| Filed 2021-02-04 12:18 Tx date 2021-02-02 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark Stephen
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
+235,322 vol |
457,415 | |
| Filed 2021-02-04 12:17 Tx date 2021-02-02 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark Stephen
5 - Senior Officer of Issuer
Direct Ownership
|
Rights RSUs
57 - Exercise of rights
|
-330,000 vol |
340,000 | |
| Filed 2021-02-04 12:16 Tx date 2021-02-02 |
$AGN
Algernon Pharmaceuticals Inc. |
Levine, David
4 - Director of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
+73,118 vol |
143,722 | |
| Filed 2021-02-04 12:15 Tx date 2021-02-02 |
$AGN
Algernon Pharmaceuticals Inc. |
Levine, David
4 - Director of Issuer
Direct Ownership
|
Rights RSUs
57 - Exercise of rights
|
-82,500 vol |
85,000 | |
| Filed 2021-02-04 12:14 Tx date 2021-02-02 |
$AGN
Algernon Pharmaceuticals Inc. |
Sadhra, Michael
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
+252,611 vol |
606,667 | |
| Filed 2021-02-04 12:13 Tx date 2021-02-02 |
$AGN
Algernon Pharmaceuticals Inc. |
Sadhra, Michael
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Rights RSUs
57 - Exercise of rights
|
-330,000 vol |
340,000 | |
| Filed 2021-02-04 12:11 Tx date 2021-02-02 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
+283,989 vol |
1,452,777 | |
| Filed 2021-02-04 12:10 Tx date 2021-02-02 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Rights RSUs
57 - Exercise of rights
|
-412,500 vol |
425,000 | |
| Filed 2020-12-18 19:43 Tx date 2020-09-29 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark Stephen
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
+222,093 vol |
222,093 | |
| Filed 2020-12-18 19:42 Tx date 2020-09-29 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark Stephen
5 - Senior Officer of Issuer
Direct Ownership
|
Rights RSUs
57 - Exercise of rights
|
-330,000 vol |
670,000 | |
| Filed 2020-12-18 19:40 Tx date 2020-09-29 |
$AGN
Algernon Pharmaceuticals Inc. |
Levine, David
4 - Director of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
+70,604 vol |
70,604 | |
| Filed 2020-12-18 19:39 Tx date 2015-12-14 |
$AGN
Algernon Pharmaceuticals Inc. |
Levine, David
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2020-12-18 19:39 Tx date 2020-09-29 |
$AGN
Algernon Pharmaceuticals Inc. |
Levine, David
4 - Director of Issuer
Direct Ownership
|
Rights RSUs
57 - Exercise of rights
|
-82,500 vol |
167,500 | |
| Filed 2020-12-18 19:36 Tx date 2020-09-29 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
+268,788 vol |
1,168,788 | |
| Filed 2020-12-18 19:36 Tx date 2020-09-29 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Rights RSUs
57 - Exercise of rights
|
-412,500 vol |
837,500 | |
| Filed 2020-12-18 19:33 Tx date 2020-09-29 |
$AGN
Algernon Pharmaceuticals Inc. |
Sadhra, Michael
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Rights RSUs
57 - Exercise of rights
|
-330,000 vol |
670,000 | |
| Filed 2020-12-18 19:27 Tx date 2020-09-29 |
$AGN
Algernon Pharmaceuticals Inc. |
Sadhra, Michael
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
+240,149 vol |
504,056 | |
| Filed 2020-12-18 19:26 Tx date 2020-09-29 |
$AGN
Algernon Pharmaceuticals Inc. |
Sadhra, Michael
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Rights RSUs
57 - Exercise of rights
|
-240,149 vol |
||
| Filed 2020-12-18 19:23 Tx date 2020-12-15 |
$AGN
Algernon Pharmaceuticals Inc. |
Sadhra, Michael
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-46,500
-150,000 vol $0.31 each |
354,056 | |
| Filed 2020-12-18 19:22 Tx date 2020-09-29 |
$AGN
Algernon Pharmaceuticals Inc. |
Sadhra, Michael
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
+330,000 vol |
||
| Filed 2020-12-18 19:19 Tx date 2020-09-29 |
$AGN
Algernon Pharmaceuticals Inc. |
Sadhra, Michael
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Rights RSUs
57 - Exercise of rights
|
-330,000 vol |
||
| Filed 2020-08-27 13:34 Tx date 2020-08-21 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark Stephen
5 - Senior Officer of Issuer
Direct Ownership
|
Rights RSUs
56 - Grant of rights
|
+1,000,000 vol |
1,000,000 | |
| Filed 2020-08-27 13:33 Tx date 2018-10-22 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark Stephen
5 - Senior Officer of Issuer
Direct Ownership
|
Rights RSUs
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2020-08-27 13:32 Tx date 2020-08-21 |
$AGN
Algernon Pharmaceuticals Inc. |
Sadhra, Michael
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Rights RSUs
56 - Grant of rights
|
+1,000,000 vol |
1,000,000 | |
| Filed 2020-08-27 13:30 Tx date 2020-08-21 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Rights RSUs
56 - Grant of rights
|
+1,250,000 vol |
1,250,000 | |
| Filed 2020-08-27 13:27 Tx date 2018-03-01 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Rights RSUs
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2020-08-27 12:16 Tx date 2015-10-26 |
$AGN
Algernon Pharmaceuticals Inc. |
Levine, David
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+200,000 vol |
||
| Filed 2020-08-27 12:16 Tx date 2015-12-14 |
$AGN
Algernon Pharmaceuticals Inc. |
Levine, David
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
200,000 | ||
| Filed 2020-08-27 12:14 Tx date 2020-04-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Levine, David
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+200,000 vol |
700,000 | |
| Filed 2020-08-27 12:13 Tx date 2020-02-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Levine, David
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+200,000 vol |
500,000 | |
| Filed 2020-08-27 12:12 Tx date 2018-03-01 |
$AGN
Algernon Pharmaceuticals Inc. |
Levine, David
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+50,000 vol |
300,000 | |
| Filed 2020-08-27 12:11 Tx date 2017-05-18 |
$AGN
Algernon Pharmaceuticals Inc. |
Levine, David
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+50,000 vol |
250,000 | |
| Filed 2020-08-27 12:10 Tx date 2015-10-26 |
$AGN
Algernon Pharmaceuticals Inc. |
Levine, David
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+200,000 vol |
||
| Filed 2020-08-27 12:09 Tx date 2015-12-14 |
$AGN
Algernon Pharmaceuticals Inc. |
Levine, David
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2020-08-27 12:08 Tx date 2020-08-21 |
$AGN
Algernon Pharmaceuticals Inc. |
Levine, David
4 - Director of Issuer
Direct Ownership
|
Rights RSUs
56 - Grant of rights
|
+250,000 vol |
250,000 | |
| Filed 2020-08-27 12:07 Tx date 2015-12-14 |
$AGN
Algernon Pharmaceuticals Inc. |
Levine, David
4 - Director of Issuer
Direct Ownership
|
Rights RSUs
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2020-08-27 12:05 Tx date 2020-08-21 |
$AGN
Algernon Pharmaceuticals Inc. |
Sadhra, Michael
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Rights RSUs
56 - Grant of rights
|
+1,000,000 vol |
1,000,000 | |
| Filed 2020-08-27 12:05 Tx date 2020-08-21 |
$AGN
Algernon Pharmaceuticals Inc. |
Sadhra, Michael
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Rights RSUs
56 - Grant of rights
|
+1,000,000 vol |
||
| Filed 2020-08-27 12:03 Tx date 2015-10-26 |
$AGN
Algernon Pharmaceuticals Inc. |
Sadhra, Michael
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Rights RSUs
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2020-07-16 09:36 Tx date 2018-10-17 |
$AGN
Algernon Pharmaceuticals Inc. |
Sadhra, Michael
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
$-36,000
-150,000 vol $0.24 each |
400,000 | |
| Filed 2020-07-16 09:35 Tx date 2018-10-17 |
$AGN
Algernon Pharmaceuticals Inc. |
Sadhra, Michael
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
$-37,500
-250,000 vol $0.15 each |
550,000 | |
| Filed 2020-07-16 09:31 Tx date 2018-10-17 |
$AGN
Algernon Pharmaceuticals Inc. |
Sadhra, Michael
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
37 - Stock split or consolidation
|
-381,250 vol |
381,250 | |
| Filed 2020-07-16 09:28 Tx date 2019-11-25 |
$AGN
Algernon Pharmaceuticals Inc. |
Sadhra, Michael
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
55 - Expiration of warrants
|
$-118,750.05
-791,667 vol $0.15 each |
0 | |
| Filed 2020-06-23 20:27 Tx date 2020-04-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark Stephen
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+1,250,000 vol |
1,750,000 | |
| Filed 2020-06-23 20:26 Tx date 2020-02-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark Stephen
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+500,000 vol |
500,000 | |
| Filed 2020-06-23 20:24 Tx date 2018-10-22 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark Stephen
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2020-06-23 20:24 Tx date 2018-10-22 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark Stephen
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2020-06-12 15:12 Tx date 2020-04-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+1,250,000 vol |
2,000,000 | |
| Filed 2020-06-12 15:11 Tx date 2020-02-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+500,000 vol |
750,000 | |
| Filed 2020-06-12 15:10 Tx date 2018-10-17 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
-250,000 vol |
250,000 | |
| Filed 2020-06-12 15:06 Tx date 2017-10-17 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
37 - Stock split or consolidation
|
-250,000 vol |
||
| Filed 2020-06-12 15:06 Tx date 2018-03-01 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2019-06-05 11:51 Tx date 2017-10-17 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
37 - Stock split or consolidation
|
-250,000 vol |
||
| Filed 2019-06-05 11:49 Tx date 2018-03-01 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2020-04-15 11:32 Tx date 2020-04-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Sadhra, Michael
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$290,000
+1,000,000 vol $0.29 each |
2,800,000 | |
| Filed 2020-03-02 23:09 Tx date 2020-02-25 |
$AGN
Algernon Pharmaceuticals Inc. |
Attariwala, Rajpaul
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+200,000 vol |
650,000 | |
| Filed 2020-02-26 12:45 Tx date 2020-02-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Sadhra, Michael
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$100,000
+1,000,000 vol $0.10 each |
1,800,000 | |
| Filed 2020-01-09 14:57 Tx date 2020-01-02 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$3,250
+50,000 vol $0.065 each |
880,000 | |
| Filed 2020-01-09 14:57 Tx date 2020-01-02 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$3,000
+50,000 vol $0.06 each |
830,000 | |
| Filed 2020-01-09 14:54 Tx date 2020-01-03 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$1,300
+20,000 vol $0.065 each |
900,000 | |
| Filed 2020-01-03 06:17 Tx date 2020-01-02 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
+100,000 vol |
||
| Filed 2020-01-03 06:17 Tx date 2020-01-02 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
+100,000 vol |
880,000 | |
| Filed 2019-09-30 21:17 Tx date 2019-09-27 |
$AGN
Algernon Pharmaceuticals Inc. |
Malhi, Kulwant
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$16,500
+150,000 vol $0.11 each |
510,501 | |
| Filed 2019-07-23 13:55 Tx date 2019-02-08 |
$AGN
Algernon Pharmaceuticals Inc. |
Malhi, Kulwant
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$8,845
+29,000 vol $0.305 each |
360,501 | |
| Filed 2019-07-23 13:54 Tx date 2019-02-08 |
$AGN
Breathtec BioMedical, Inc. |
Malhi, Kulwant
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$8,845
+29,000 vol $0.305 each |
||
| Filed 2019-02-09 14:04 Tx date 2019-02-08 |
$AGN
Breathtec BioMedical, Inc. |
Malhi, Kulwant
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$8,845
+29,000 vol $0.305 each |
||
| Filed 2019-06-05 11:54 Tx date 2019-05-24 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$7,200
+30,000 vol $0.24 each |
780,000 | |
| Filed 2019-06-05 11:53 Tx date 2018-10-22 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
+750,000 vol |
750,000 | |
| Filed 2019-06-05 11:52 Tx date 2018-03-01 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2019-06-05 11:51 Tx date 2017-10-17 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
37 - Stock split or consolidation
|
-250,000 vol |
250,000 | |
| Filed 2019-06-05 11:49 Tx date 2018-03-01 |
$AGN
Algernon Pharmaceuticals Inc. |
Moreau, Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
500,000 | ||
| Filed 2019-04-09 16:52 Tx date 2019-03-21 |
$AGN
Algernon Pharmaceuticals Inc. |
Sadhra, Michael
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-27,692.948
-117,343 vol $0.236 each |
645,157 |